Literature DB >> 15758163

Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS.

Tim Magnus1, Bettina Schreiner, Thomas Korn, Carolyn Jack, Hong Guo, Jack Antel, Igal Ifergan, Lieping Chen, Felix Bischof, Amit Bar-Or, Heinz Wiendl.   

Abstract

Inflammation of the CNS is usually locally limited to avoid devastating consequences. Critical players involved in this immune regulatory process are the resident immune cells of the brain, the microglia. Interactions between the growing family of B7 costimulatory ligands and their receptors are increasingly recognized as important pathways for costimulation and/or inhibition of immune responses. Human and mouse microglial cells constitutively express B7 homolog 1 (B7-H1) in vitro. However, under inflammatory conditions [presence of interferon-gamma (IFN-gamma) or T-helper 1 supernatants], a significant upregulation of B7-H1 was detectable. Expression levels of B7-H1 protein on microglial cells were substantially higher compared with astrocytes or splenocytes. Coculture experiments of major histocompatibility complex class II-positive antigen-presenting cells (APC) with syngeneic T cells in the presence of antigen demonstrated the functional consequences of B7-H1 expression on T-cell activation. In the presence of a neutralizing anti-B7-H1 antibody, both the production of inflammatory cytokines (IFN-gamma and interleukin-2) and the upregulation of activation markers (inducible costimulatory signal) by T cells were markedly enhanced. Interestingly, this effect was clearly more pronounced when microglial cells were used as APC, compared with astrocytes or splenocytes. Furthermore, B7-H1 was highly upregulated during the course of myelin oligodendrocyte glycoprotein-induced and proteolipid protein-induced experimental allergic encephalomyelitis in vivo. Expression was predominantly localized to areas of strongest inflammation and could be colocalized with microglial cells/macrophages as well as T cells. Together, our data propose microglial B7-H1 as an important immune inhibitory molecule capable of downregulating T-cell activation in the CNS and thus confining immunopathological damage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15758163      PMCID: PMC6725171          DOI: 10.1523/JNEUROSCI.4794-04.2005

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  58 in total

Review 1.  Activation-induced apoptosis of autoreactive and alloreactive T lymphocytes in the target organ as a major mechanism of tolerance.

Authors:  M P Pender
Journal:  Immunol Cell Biol       Date:  1999-06       Impact factor: 5.126

2.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.

Authors:  H Dong; G Zhu; K Tamada; L Chen
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

Review 3.  The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function.

Authors:  A J Coyle; J C Gutierrez-Ramos
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

Review 4.  Brain-immune connection: immuno-regulatory properties of CNS-resident cells.

Authors:  B Becher; A Prat; J P Antel
Journal:  Glia       Date:  2000-02-15       Impact factor: 7.452

5.  Microglia induce myelin basic protein-specific T cell anergy or T cell activation, according to their state of activation.

Authors:  M K Matyszak; S Denis-Donini; S Citterio; R Longhi; F Granucci; P Ricciardi-Castagnoli
Journal:  Eur J Immunol       Date:  1999-10       Impact factor: 5.532

6.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

7.  FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier.

Authors:  I Bechmann; G Mor; J Nilsen; M Eliza; R Nitsch; F Naftolin
Journal:  Glia       Date:  1999-07       Impact factor: 7.452

8.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.

Authors:  H Nishimura; M Nose; H Hiai; N Minato; T Honjo
Journal:  Immunity       Date:  1999-08       Impact factor: 31.745

9.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

10.  In situ tolerance within the central nervous system as a mechanism for preventing autoimmunity.

Authors:  T Brabb; P von Dassow; N Ordonez; B Schnabel; B Duke; J Goverman
Journal:  J Exp Med       Date:  2000-09-18       Impact factor: 14.307

View more
  69 in total

Review 1.  The adaptive immune system in diseases of the central nervous system.

Authors:  David C Wraith; Lindsay B Nicholson
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 2.  PD-1, gender, and autoimmunity.

Authors:  Ravi K Dinesh; Bevra H Hahn; Ram Pyare Singh
Journal:  Autoimmun Rev       Date:  2010-04-28       Impact factor: 9.754

3.  PD-1 signalling in CD4(+) T cells restrains their clonal expansion to an immunogenic stimulus, but is not critically required for peptide-induced tolerance.

Authors:  Joanne E Konkel; Friederike Frommer; Melanie D Leech; Hideo Yagita; Ari Waisman; Stephen M Anderton
Journal:  Immunology       Date:  2010-01-27       Impact factor: 7.397

Review 4.  The innate immune system in demyelinating disease.

Authors:  Lior Mayo; Francisco J Quintana; Howard L Weiner
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 5.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 6.  CNS immune privilege: hiding in plain sight.

Authors:  Monica J Carson; Jonathan M Doose; Benoit Melchior; Christoph D Schmid; Corinne C Ploix
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

7.  Enhanced antiviral T cell function in the absence of B7-H1 is insufficient to prevent persistence but exacerbates axonal bystander damage during viral encephalomyelitis.

Authors:  Timothy W Phares; Stephen A Stohlman; David R Hinton; Roscoe Atkinson; Cornelia C Bergmann
Journal:  J Immunol       Date:  2010-09-27       Impact factor: 5.422

Review 8.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

9.  Inflammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor Progression.

Authors:  Rui Pedro Galvão; Hui Zong
Journal:  Curr Pathobiol Rep       Date:  2013-03-01

10.  Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants.

Authors:  Antje Kroner; Nicholas Schwab; Chi Wang Ip; Sonja Ortler; Kerstin Göbel; Klaus-Armin Nave; Mathias Mäurer; Rudolf Martini; Heinz Wiendl
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.